Bilateral ureteral obstruction (BUO) in rats is associated with increased cyclooxygenase type 2 (COX-2) expression, and selective COX-2 inhibition prevents downregulation of aquaporins (AQPs) in response to BUO. It was hypothesized that a murine model would display similar changes in renal COX-2 and AQPs upon BUO and that targeted disruption of COX-2 protects against BUO-induced suppression of collecting duct AQPs. COX-2 Ϫ/Ϫ and wild-type littermates (C57BL/6) were employed to determine COX-1, -2, AQP2, and AQP3 protein abundances and localization after BUO. In a separate series, sham and BUO wild-type mice were treated with a selective COX-2 inhibitor, parecoxib. The COX-2 protein level increased in wild-type mice in response to BUO and was not detectable in COX-2 Ϫ/Ϫ . COX-1 protein abundance was increased in sham-operated and BUO mice. Total AQP2 and -3 mRNA and protein levels decreased significantly after BUO in the cortexϩouter medulla (CϩOM) and inner medulla (IM). The decrease in CϩOM AQP2 and -3 levels was attenuated/prevented in COX-2 Ϫ/Ϫ mice, whereas there was no change in the IM. In parallel, inhibition of COX-2 by parecoxib rescued CϩOM AQP3 and IM AQP2 protein level in wild-type mice subjected to BUO. In summary, 1) In C57BL/6 mice, ureteral obstruction increases renal COX-2 expression in interstitial cells and lowers AQP2/-3 abundance and 2) inhibition of COX-2 activity by targeted disruption or pharmacological blockade attenuates obstructioninduced AQP downregulation. In conclusion, COX-2-derived prostaglandins contribute to downregulation of transcellular water transporters in the collecting duct and likely to postobstruction diureses in the mouse.
PGF 1␣ , and thromboxane-2 in rat kidney tissue in response to BUO (18) .
It is well established that BUO and release of BUO is associated with a marked decrease in renal aquaporin (AQP) levels and collecting duct water permeability (6, 12, 16) . Previously, it was demonstrated that selective COX-2 inhibition prevents downregulation of AQP2 in response to BUO in the inner medulla (IM) (16 -18) and restores urine output toward normal in the first hours after release of obstruction in rats (1) . The major effect of prostaglandins on water transport appears to be mediated by the binding of PGE 2 to the EP 3 receptor, subsequently inhibiting increased intracellular cAMP, thereby hindering vasopressin-mediated delivery of AQP2 to the plasma membrane in cortical collecting duct principal cells (7, 25) . However, a recent study showed that prolonged treatment with a selective EP 4 receptor agonist of a mice model in which the V2 vasopressin receptor (V2R) gene is conditionally deleted prevents downregulation of renal AQP2 levels, probably due to EP 4 receptor-mediated elevation of cAMP levels in kidney collecting duct cells (14) . Moreover, Olesen et al. (21) demonstrated that EP 2 and EP 4 agonists increase both AQP2 phosphorylation and trafficking. We have demonstrated that COX-2 knockout mice (COX-2 Ϫ/Ϫ ) exhibit lower urine concentrating ability despite increased AQP2 and AQP3 abundances (19) . Taken together, these contradictory observations on the regulatory impact of prostaglandins on renal aquaporin abundance/water transport prompt investigations into model systems where the contribution from distinct components of the very redundant system can be defined more precisely. Thus, to gain insight into the role of COX-2 in the obstruction-induced renal AQP changes and overcome the inherent challenges associated with drug specificity in pharmacological approaches, we decided to transfer from a rat to a murine model system and employ mice with targeted disruption of COX-2. We hypothesized that complete ureteral obstruction in the mouse leads to increased renal COX-2 expression and COX-2-dependent downregulation of collecting duct AQP2 and AQP3. To address this question, COX-2 Ϫ/Ϫ and wild-type littermate mice on a C57BL/6 background were used for the experiments. The mild developmental renal injury in COX-2 Ϫ/Ϫ on a C57BL/6 background (19, 29) with higher levels of AQP2 and AQP3 was not considered a drawback to test the present hypothesis regarding downregulation of AQPs in response to BUO. Wild-type and COX-2 Ϫ/Ϫ mice were subjected to BUO for 24 h, and renal tissue abundance and localization of COX-2, COX-1, and collecting duct AQP2 and -3 were determined. To ensure that observations were caused by abolished COX-2 activity, experiments were repeated in wild-type mice that were treated with the selective COX-2 inhibitor parecoxib during 24-h BUO.
MATERIALS AND METHODS

COX-2
Ϫ/Ϫ Mice COX-2 Ϫ/Ϫ mice on a mixed 129/C57 background were originally generated by Dinchuk et al. (3) . The breeder pairs were obtained from The Jackson Laboratory (Bar Harbor, ME) on a predominant C57BL/6J background. Animals were further backcrossed to the C57BL/6J genetic background for two consecutive generations before they were used for experiments. Mice were housed at The Biomedical Laboratory, University of Southern Denmark and genotyped as previously described (5) . All procedures conformed to the Danish National Guidelines for the care and handling of animals and the published guidelines from the National Institutes of Health. The animal protocols were approved by the board of the Institute of Clinical Medicine, Aarhus University, according to the licenses for use of experimental animals issued by the Danish Ministry of Justice.
Experimental Animals
Studies were performed in COX-2 Ϫ/Ϫ and wild-type mice. The animals had free access to a standard rodent diet (Altromin, Lage, Germany) and tap water. During the experiments, animals were kept in individual cages, with a 12:12-h light-dark cycle, a temperature of 21 Ϯ 2°C, and a humidity of 55 Ϯ 2%. Animals were allowed to acclimatize to the cages 3-4 days before surgery. The animals were placed on anesthesia with isoflurane (Abbott Scandinavia), and during the operation the animals were placed on a heating pad to maintain rectal temperature at 37-38°C. Through a midline abdominal incision, both ureters were exposed and then occluded with a silk ligature.
Animals were allocated to the protocols indicated below. Ageand time-matched, sham-operated controls were prepared and were observed in parallel with each BUO group in the following protocols. Protocol 1. BUO was induced for 24 h in COX-2 Ϫ/Ϫ and wild-type mice (n ϭ 10). The kidneys were prepared for semiquantitative immunoblotting and quantitative PCR (QPCR; n ϭ 6) or for immunohistochemistry (n ϭ 4). Sham-operated controls were prepared in parallel (n ϭ 9), and the kidneys were prepared for semiquantitative immunoblotting and QPCR (n ϭ 6) or for immunohistochemistry (n ϭ 3).
Protocol 2. Prior to surgery, wild-type mice were injected with a selective COX-2 inhibitor, parecoxib (Pfizer), dissolved in saline (5 mg·kg Ϫ1 ·day Ϫ1 ) for 7 days. Injections with saline as a control were conducted in parallel. BUO was induced for 24 h in mice in both parecoxib-treated (n ϭ 5) and saline-treated (n ϭ 6) mice. Shamoperated controls were prepared in parallel in both parecoxib-treated (n ϭ 4) and saline treated (n ϭ 6) mice. The kidneys were prepared for semiquantitative immunoblotting.
Administration of a dose at 5 mg·kg Ϫ1 ·day Ϫ1 parecoxib was chosen according to a pharmacological profile study of parecoxib (23) .
Blood Sampling and Removal of Kidneys
Twenty-four hours after induction of BUO, mice were reanesthetized with isoflurane. Before death, the aortic bifurcation of the mouse was localized, dissected free, and a blood sample was collected for the determination of plasma electrolytes and osmolality. Rapidly, the kidneys were removed and dissected into the cortex and IM. The plasma concentrations of sodium, potassium, creatinine, and urea were measured (Vitros 950, Johnson&Johnson). Finally, the osmolality of the plasma was determined with a vapor pressure osmometer (Osmomat 030, Gonotec, Berlin, Germany).
Isolation of RNA and QPCR
Total RNA was isolated from mouse cortex and IM with a NucleoSpin RNA II mini kit according to the manufacturer's instructions (Macherey-Nagel). RNA was quantitated by spectrophotometry and stored at Ϫ80°C. cDNA synthesis was performed on 0.5 g RNA with an AffinityScript QPCR cDNA synthesis kit (Stratagene).
For QPCR, 100 ng cDNA served as a template for PCR amplification using Brilliant SYBR Green QPCR Master Mix according to the manufacturer's instructions (Stratagene). Serial dilution (1 ng-1 fg/l) of cDNA was used as a template for generation of a standard curve. Nested primers were used to amplify standards and kidney cDNA samples: COX-2: sense 5=-GCA GCC AGT TGT CAA ACT GC-3=; antisense 5=-CTC GGA AGA GCA TCG CAG AGG-3=; GenBank accession no. NM_011198.2; AQP2: sense 5=-CTT CCT TCG AGC TGC CTT C-3=; antisense 5=-CAT TGT TGT GGA GAG CAT TGA C-3=; GenBank accession no. NM_009699.2; AQP3: sense 5=-TGT GTG TAC TGG CCA TCG TT-3=; antisense 5=-GTT GAC GGC ATA GCC AGA AT-3=; GenBank accession no. AF104416.1; AQP4: sense 5=-GCA TCG CTA AGT CCG TCT TC-3=; antisense 5=-GGG AGG TGT GAC CAG GTA GA-3=; GenBank accession no. U88623; and GAPDH: sense 5=-TAA AGG GCA TCC TGG GCT ACA CT-3=; antisense 5=-TTA CTC CTT GGA GGC CAT GTA GG-3=; GenBank accession no. M32599.1. Standards and unknown samples were amplified in duplicate in 96-well plates, and PCR was performed for 40 cycles consisting of denaturation for 30 s at 95°C followed by annealing and polymerization at 60°C for 1 min. Emitted fluorescence was detected during the annealing/extension step in each cycle. A post-run melting-curve analysis was performed to ensure only one amplification product. Selected samples were subjected to gel electrophoresis to confirm the expected size of the product and only one product.
Membrane Fractionation for Immunoblotting
The tissue [cortexϩouter medulla (CϩOM) and IM] was homogenized in dissecting buffer (0.3 M sucrose, 25 mM imidazole, 1 mM EDTA, pH 7.2) containing the following protease inhibitors: 8.5 M leupeptin (serine and cysteine protease inhibitor, SigmaAldrich, St. Louis, MO) and 0.4 mM Pefabloc (serine protease inhibitor, Roche). The tissue was homogenized (30 s at 1,250 rpm) by an Ultra-Turrax T8 homogenizer (IKA Labortechnik) and then centrifuged at 4,500 g at 4°C for 15 min. Gel samples were prepared from the supernatant in Laemmli sample buffer contain- ing 2% SDS. The total protein concentration of the homogenate was measured using a Pierce BCA protein assay kit (Roche).
Electrophoresis and Immunoblotting
Samples of membrane fractionation from the different zones were run on 12% polyacrylamide minigels (Bio-Rad Mini Protean II). For each gel, an identical gel was run in parallel and subjected to Coomassie staining. The Coomassie-stained gel was applied to determine identical loading or to allow for correction for minor variations in loading.
Samples were run on 12% polyacrylamide gels (Bio-Rad Protean II). Proteins were transferred to a nitrocellulose membrane (Hybond ECL RPN 3032D, Amersham Pharmacia Biotech). Afterward, the blots were blocked with 5% nonfat dry milk in PBS-T (80 mM Na 2HPO4, 20 mM NaH2PO4, 100 mM NaCl, 0.1 Tween 20, adjusted to pH 7.4). After washing in PBS-T, the blots were incubated with primary antibodies overnight at 4°C. The antigen-antibody complex was visualized with horseradish peroxidase (HRP)-conjugated secondary antibodies (P448, diluted 1:3,000, Dako, Glostrup, Denmark) using the enhanced chemiluminescence system (ECL; Amersham Pharmacia Biotech). Immunolabeling controls were performed using peptide-absorbed antibody. bridge, UK); COX-1 (160109, Cayman Chemical); and AQPs, which had been well characterized in previous studies: AQP-2 (H7661) (15), pAQP2Ser256 (KO407) (2), AQP-3 (LL178AP) (4).
Primary Antibodies
Immunohistochemistry
The kidneys from BUO and sham-operated control mice were fixed by retrograde perfusion via the abdominal aorta with 3% paraformaldehyde in 0.1 M cacodylate buffer, pH 7.4. Moreover the kidneys were immersion fixed for 1 h and washed for 3 ϫ 10 min with 0.1 M cacodylate buffer. The kidney blocks were dehydrated and embedded in paraffin. The paraffin-embedded tissues were cut in 2-m sections on a rotary microtome (Leica Microsystems, Herlev, Denmark).
For immunoperoxidase labeling, the sections were deparaffinated and rehydrated. Endogenous peroxidase activity was blocked with 5% H 2O2 in absolute methanol for 10 min at room temperature. To expose antigens, kidney sections were boiled in a target retrieval solution (1 mmol/l Tris, pH 9.0, with 0.5 mM EGTA) for 10 min. After cooling, nonspecific binding was prevented by incubating the sections in 50 mM NH 4Cl in PBS for 30 min, followed by blocking in PBS containing 1% BSA, 0.05% saponin, and 0.2% gelatin. Sections were incubated with primary antibodies diluted in PBS with 0.1% BSA and 0.3% Triton X-100 overnight at 4°C. After being washed 3 ϫ 10 min with PBS supplemented with 0.1% BSA, 0.05% saponin, and 0.2% gelatin, the sections were incubated with HRP-conjugated secondary antibody (P448, goat anti-rabbit immunoglobulin, Dako) for 1 h at room temperature. After rinsing with PBS wash buffer, the sites of antibody-antigen reactions were visualized with 0.05% 3,3=-diaminobenzidine tetrachloride (Kem-en Tek, Copenhagen, Denmark) dissolved in distilled water with 0.1% H 2O2. The light microscope was carried out with Lecia DMRE (Leica Microsystems).
Statistics
Values are means Ϯ SE. Statistical comparison of two experimental groups was performed by an unpaired Student's t-test. When several groups were compared, this was done by two-way ANOVA followed by post hoc analysis with a t-test and Bonferroni correction. P values Ͻ 0.05 were considered significant.
RESULTS
Effect of BUO on Kidney Weight, Plasma Electrolytes, Creatinine, and Osmolality in Wild-Type and COX-2 Ϫ/Ϫ
Mice
There was no significant difference between wild-type and COX-2 Ϫ/Ϫ sham-operated mice with regard to body weight or plasma concentration of sodium and potassium (Table 1) . At baseline, the kidney/body weight ratio was lower, and plasma urea, creatinine, and osmolality were elevated significantly in sham-operated COX-2 Ϫ/Ϫ compared with wild-type mice (Table 1). After introduction of BUO in both wild-type and COX-2 Ϫ/Ϫ mice, kidney weight, plasma osmolality, potassium, creatinine, and urea increased significantly compared with sham-operated control mice (Table 1) . Apart from increased plasma potassium in COX-2 Ϫ/Ϫ mice, there was no significant difference in the parameters between genotypes after BUO.
Changed COX-2 and COX-1 Expression in Wild-Type Mice in Response to BUO
The abundance of COX-2 mRNA and protein was significantly increased in CϩOM tissue homogenates in wild-type mice in response to BUO (Fig. 1, A and B) . In IM homogenates, the COX-2 protein level was increased in BUO wildtype mice (Fig. 1C) . In COX-2 Ϫ/Ϫ mice, there was no detectable COX-2 mRNA or protein level (Fig. 1, A-C) . Experiments with IM homogenates revealed that the anti-COX-2 antibody (Cayman 160126) labeled a protein of the expected molecular size (ϳ72 kDa). This was completely ablated when the antibody was preincubated with an excess of the immunizing peptide (Fig. 1D) . To further support the specificity, additional analyses were conducted with different antibodies directed against COX-2 (Cayman 160106 and Abcam ab15191). Both antibodies confirmed the COX-2 result in response to BUO and further corroborate the findings (Fig. 1D) . Immunohistochemical staining of kidney IM sections revealed that COX-2-immunoreactive protein was localized to the medullary interstitial cells in the obstructed kidney, and there was no detectable labeling in the COX-2 Ϫ/Ϫ mice subjected to BUO (Fig. 1,  E and F) . At baseline, mice deficient in COX-2 showed a significant increase in COX-1 protein abundance in both CϩOM and IM (Fig. 2, A and B) . In wild-type mice, COX-1 protein abundance increased after BUO in both CϩOM and IM compared with sham-operated animals (Fig. 2, A and B) ; in CϩOM of COX-2 Ϫ/Ϫ mice, COX-1 expression increased further in response to BUO whereas it was unaltered at a high level in the IM (Fig. 2, A and B) .
Effect of BUO on Renal AQP2 Abundance and Localization in Wild-Type and COX-2 Ϫ/Ϫ Mice
In CϩOM fraction, total AQP2 mRNA and protein abundance significantly decreased in wild-type BUO-operated mice compared with sham-operated wild-type mice. In BUO-operated COX-2 Ϫ/Ϫ mice, downregulation of total AQP2 was attenuated at both mRNA and protein levels (Fig. 3, A and B) . Immunohistochemistry of cortical sections demonstrated that wild-type mice subjected to BUO showed weaker labeling of AQP2 in the apical plasma membranes in collecting duct principal cells compared with sham-operated wild-type mice. COX-2 Ϫ/Ϫ mice subjected to BUO showed stronger labeling of AQP2 compared with obstructed wild-type mice (Fig. 3, C-F) .
AQP2 mRNA levels in the IM did not differ between sham-operated wild-type and COX-2 Ϫ/Ϫ while it was suppressed below 5% of sham levels following obstruction in both genotypes (Fig. 4A) . Total AQP2 protein abundances in the IM did not differ between genotypes in sham-operated mice. After BUO induction, AQP2 protein abundances decreased equally in wild-type and COX-2 Ϫ/Ϫ mice compared with sham-operated mice (Fig. 4B) . However, total AQP2 protein was signif- icantly decreased in COX-2 Ϫ/Ϫ compared with wild-type mice after BUO.
The pAQP2 protein level in CϩOM did not differ between genotypes as well as sham-operated control and BUO-operated mice. In the IM, pAQP2 was significantly suppressed in both genotypes after BUO compared with wild-type mice (data not shown).
Effect of BUO on Renal AQP3 Abundance and Localization in Wild-Type and COX-2
Ϫ/Ϫ Mice AQP3 mRNA levels did not differ between genotypes in CϩOM in sham-operated mice (Fig. 5A) . However, at the protein level AQP3 was increased in the COX-2 Ϫ/Ϫ mice (Fig.  5B) . Upon obstruction, AQP3 mRNA and protein levels in CϩOM decreased significantly in wild-type mice, while deletion of COX-2 rescued the AQP3 protein level and improved the AQP3 mRNA level (Fig. 5, A and B) . Immunohistochemical labeling of kidney sections for AQP3 demonstrated that sham-operated wild-type mice displayed a less marked labeling pattern associated with cortical collecting duct basolateral membranes compared with COX-2 Ϫ/Ϫ mice (Fig. 5 , C vs. D). After obstruction, wild-type mice exhibited labeling close to the detection threshold, while labeling of COX-2 Ϫ/Ϫ kidneys subjected to BUO was indistinguishable from sham-operated COX-2 Ϫ/Ϫ mice (Fig. 5, E and F) . In the IM, AQP3 mRNA was not different between COX-2 Ϫ/Ϫ and wild-type mice, while at the protein level AQP3 was significantly increased in the sham-operated COX-2 Ϫ/Ϫ mice compared with wild-type. AQP3 mRNA level decreased significantly after BUO in COX-2 Ϫ/Ϫ and wild-type compared with sham-operated mice, while at the protein level AQP3 was only significantly reduced in the wild-type BUO-operated mice (Fig. 6, A and B) .
Effect of BUO on Renal AQP Abundance in Parecoxib-Treated and Control Mice
A last series of experiments tested the effect of a COX-2 inhibitor in sham-operated and BUO wild-type mice. Wildtype mice were treated with a COX-2 inhibitor and then subjected to sham operation or BUO, and changes in COX-1, AQP2, and -3 protein abundances were analyzed.
To examine the effect of the COX-2 inhibitor parecoxib, the cortical COX-2 mRNA level was measured in treated and untreated control mice, which demonstrated threefold increase in COX-2 expression in response to parecoxib treatment compared with control mice (COX-2/␤-actin ratio: 1.03 Ϯ 0.31 vs. 0.31 Ϯ 0.03, P Ͻ 0.05) (10, 16) . The COX-1 protein level was increased in BUO-operated mice compared with sham-operated mice in both CϩOM and IM (Fig. 7, A and D) , although it did not reach a significant level in the IM (P ϭ 0.057). Parecoxib treatment significantly increased COX-1 protein in CϩOM in sham-operated mice. AQP2 protein abundance was not significantly regulated in CϩOM in sham-operated control mice, but there was a tendency of upregulation in response to parecoxib (Fig. 7B) . In BUO-operated mice, there was a tendency toward a downregulation of AQP2 compared with sham-operated mice, although it was not significant. In the IM, AQP2 protein abundance was decreased in response to BUO, and this downregulation was attenuated by administration of parecoxib (Fig. 7E) . In response to BUO, there was a significant downregulation of pAQP2 in the IM. Treatment with parecoxib increased pAQP2 in CϩOM in sham-operated mice (data not shown). AQP3 protein abundance was significantly decreased in BUO-operated compared with sham-operated mice in CϩOM (Fig. 7C) , and a tendency of downregulation in the IM (Fig. 7F) . Administration of the selective COX-2 inhibitor parecoxib partly attenuated the decreased AQP3 protein level in CϩOM after BUO.
Immunohistochemical staining of cortical sections displayed a weaker apical AQP2 labeling in collecting duct principal cells in BUO-operated mice compared with sham-operated mice (Fig. 8, A vs. C) . Cortical labeling of AQP3 showed that vehicle-treated mice subjected to BUO display weaker labeling in the basolateral plasma membranes in collecting duct principal cells compared with sham-operated, vehicle-treated mice (Fig. 8, E vs. G) . Parecoxib-treated, BUO-operated mice exhibited stronger labeling of AQP3 compared with obstructed vehicle-treated mice, indistinguishable from sham-operated, parecoxib-treated mice (Fig. 8, E-H) .
DISCUSSION
The present study shows that BUO in wild-type mice leads to a significant induction of COX-1 and COX-2 protein and downregulation of AQP2 and -3. COX-2 displayed the largest increase after BUO and was associated with renomedullary interstitial cells. C57BL/6 mice with disrupted COX-2 (COX-2 Ϫ/Ϫ ) were protected from BUO-induced suppression of AQP2 and -3 in CϩOM tissue despite compensatory stimulation of COX-1 protein at baseline. This protection of AQP decreased protein levels by disruption of COX-2 was partially recapitulated by administration of a specific COX-2 blocker to wildtype BUO-operated mice. Thus C57BL/6 mice appear as a valid model that reproduces acute downregulation of AQPs after BUO in rats, and the data might indicate that downregulation of AQP2 and AQP3 after release of BUO and subsequent acute polyuria is mediated mainly by COX-2-derived prostaglandins.
A minor difference in rescue of AQPs in the IM between COX-2 Ϫ/Ϫ (absent protection) and parecoxib-treated wild-type (partial protection) mice was detected. This difference is likely caused by upregulated COX-1 in COX-2 Ϫ/Ϫ mice and attenuated COX-1 activity (lower abundance compared with COX-2 Ϫ/Ϫ and partial nonselective inhibition) in wild-type mice treated with parecoxib.
Changed COX-2 and COX-1 Protein Level in COX-2
Ϫ/Ϫ and Wild-Type Mice in Response to BUO BUO increases cortical and medullary COX-2 compared with sham-operated mice, and this increase is abolished in COX-2 Ϫ/Ϫ mice. Consistent with previous rat studies, the present study shows that COX-2 is increased in renal medullary interstitial cells in response to BUO (16, 18) .
As observed recently (19) , the present data confirmed that mice deficient in COX-2 display a compensatory upregulation of COX-1 and further showed that COX-1 was stimulated by BUO in the cortex. Thus the mice exhibit a larger sensitivity to BUO with more widespread upregulation of COX in kidney tissue compared with rats, for example, where cortical COX-1 and -2 did not change after BUO (16) . This differential regulation of COX-2 expression between mice and rats has been observed in previous studies with a low-salt diet, treatment with a loop diuretic, and an angiotensin-converting enzyme inhibitor in the cortex (27) .
Effect of BUO on Plasma Creatinine and Urea in Wild-Type and COX-2 Ϫ/Ϫ Mice
The observation that sham-operated COX-2 Ϫ/Ϫ mice had increased plasma creatinine and urea is consistent with previous studies in COX-2 Ϫ/Ϫ mice, suggesting reduced renal function in the COX-2 Ϫ/Ϫ mouse (19, 20, 29) . Wild-type mice with BUO exhibited a significant increase in the plasma concentration of creatinine, urea, potassium, and osmolality compared with sham-operated mice, consistent with impaired renal function and previous findings in rats (13, 16) . COX-2 Ϫ/Ϫ mice subjected to BUO showed a significant, further, increase in plasma potassium compared with obstructed wild-type mice. These results suggest that obstructed mice with homogenous deletion of COX-2 experience further reduction in renal function compared with wild-type mice subjected to BUO. COX-2 Ϫ/Ϫ mice have impaired postnatal kidney development. The defect involves cortical dysplasia, diffuse tubular dilation, hypoplastic subcapsular glomeruli, and juxtamedullary nephron hypertrophy (3, 19, 20, 22) . In the present study, COX-2 Ϫ/Ϫ mice displayed accumulation of small glomeruli in the subcapsular region, while the tissue displayed no cysts, inflammation, or fibrosis. The cortical dysplasia with fewer functional outer cortical nephrons may account for the observed changes in plasma creatinine and urea. Despite this injury, the mice were considered suitable to test the hypothesis because it relates to a pathophysiological situation where the glomerular filtration rate is reduced experimentally to a minimal level, and because the COX-2 Ϫ/Ϫ mouse exhibits AQP levels that are normal to elevated in the control situation (19) . Moreover, the mouse reacts to BUO similarly to the rat with a massive COX-2 induction in the medulla.
Effect of BUO on Renal AQP2 and AQP3 in COX-2 Ϫ/Ϫ and Parecoxib-Treated Wild-Type Mice
The present study documented downregulation of renal AQPs in response to BUO in mice, consistent with several previous rat studies (11, 16) . The downregulation of cortical AQP2 and AQP3 in response to BUO was attenuated in COX-2 Ϫ/Ϫ mice, whereas no rescue of AQP2 and AQP3 levels was observed in the IM. Why did COX-2 inhibitor experiments show protection of AQP2 abundance after BUO in the IM, similar to in rats (16) , while BUO-induced suppression of AQP2 in the IM of COX-2 Ϫ/Ϫ mice was not attenuated? A likely explanation is the compensatory upregulation of COX-1 by BUO that may supply downstream PGE synthase with substrate even in the absence of functional COX-2. At baseline, there are 25 times higher COX-1 levels in the rat IM compared with the cortex (9) . A similar gradient in the mouse with further COX-1 upregulation by BUO in COX-2 Ϫ/Ϫ mice could account for maintained or even increased prostaglandin synthesis. Parecoxib at 5 mg/kg is likely also to have some nonselective inhibitory action on COX-1 (24, 26) , which may account for the modest, but significant, attenuation of AQP2 downregulation in the IM after BUO The results further support that in the setting of BUO, COX-2-derived prostanoids either directly or by indirect pressure-related effects suppress transcellular water uptake pathways in the collecting duct. Recent observations show that PGE 2 through EP 2 /EP 4 receptors in rare situations (loss-of-function mutations in the vasopressin receptor) may actually preserve collecting duct AQPs and support urine concentrating ability (14) . In BUO, there is significant stimulation of prostaglandin synthesis in the renal medulla, while in nephrogenic diabetes insipidus, medullary prostaglandin synthesis is maximally suppressed (8, 18, 28) . These very different physiological settings probably account for the different roles associated with prostaglandins to control AQPs.
In summary, the present data show that 1) the mouse essentially recapitulates the observations from the rat that ureteral obstruction induces renal COX-2 expression and lowers aquaporin abundance and 2) inhibition of COX-2 activity by targeted disruption or pharmacological blockade in the mouse attenuates obstruction-induced AQP downregulation. The data further support that COX-2-derived prostaglandins contribute to postobstruction diureses and mice with targeted disruption of key signaling molecules could be employed to dissect the cellular events that injure kidney structure and function after ureteral obstruction.
